| Trial ID: | L7298 |
| Source ID: | NCT01951651
|
| Associated Drug: |
Exenatide
|
| Title: |
Effect of Exenatide on Liver and Heart Fat and Inflammation
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01951651/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Exenatide|DRUG: Glipizide
|
| Outcome Measures: |
Primary: Myocardial Fat Content, Myocardial fat content following intervention as measured by magnetic resonance imaging and spectroscopy (MRS) in patients with type 2 diabetes., 6 months|Hepatic Fat Content, Hepatic fat content following intervention in patients with type 2 diabetes, 6 months | Secondary: Left Ventricular Ejection Fraction (LVEF)(%)., Left Ventricular Ejection Fraction following intervention as measured by magnetic resonance imaging in patients with type 2 diabetes., 6 months|Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%), The percentage change in monocyte inflammatory proteins NFkappaB (%) from baseline., 6 months
|
| Sponsor/Collaborators: |
Sponsor: Baylor College of Medicine
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-04
|
| Completion Date: |
2013-03
|
| Results First Posted: |
2016-04-15
|
| Last Update Posted: |
2016-05-16
|
| Locations: |
Baylor College of Medicine, Houston, Texas, 77030, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01951651
|
